Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study on Early Lyme Neuroborreliosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2017 by University Medical Centre Ljubljana
Information provided by (Responsible Party):
Franc Strle, University Medical Centre Ljubljana Identifier:
First received: May 28, 2009
Last updated: May 4, 2017
Last verified: May 2017
The purpose of this study is to determine clinical course and the sequelae of early Lyme neuroborreliosis after treatment with ceftriaxone.

Condition Intervention
Nervous System Lyme Borreliosis
Drug: ceftriaxone

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Other
Official Title: Clinical and Microbiological Parameters in Patients With Early Lyme Neuroborreliosis

Resource links provided by NLM:

Further study details as provided by University Medical Centre Ljubljana:

Primary Outcome Measures:
  • Objective sequelae and post-treatment subjective symptoms in patients treated with ceftriaxone for early Lyme neuroborreliosis [ Time Frame: 1 year follow-up ]

Secondary Outcome Measures:
  • Comparison of subjective symptoms between patients treated with ceftriaxone for early Lyme neuroborreliosis and control subjects without a history of Lyme borreliosis [ Time Frame: 1 year follow-up ]

Estimated Enrollment: 50
Study Start Date: June 2009
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Early Lyme neuroborreliosis patients Drug: ceftriaxone
ceftriaxone 2 g od i.v. for 14 days
No Intervention: control subjects
Control subjects without a history of Lyme borreliosis.


Ages Eligible for Study:   15 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • erythema migrans within 4 months before neurologic involvement and pleocytosis in patients >15 years old

Exclusion Criteria:

  • pregnancy
  • lactation
  • history of adverse reaction to a beta-lactam antibiotic
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00910533

Contact: Dasa Stupica, MD +38615222110
Contact: Franc Strle, MD +38615222110

UMC Ljubljana, Department of Infectious Diseases Recruiting
Ljubljana, Slovenia, 1525
Contact: Dasa Stupica, MD    +386 1 522 2110   
Contact: Franc Strle, MD    +386 1 5222610   
Principal Investigator: Dasa Stupica, M.D., PhD         
Sub-Investigator: Katarina Ogrinc, M.D., PhD         
Sub-Investigator: Petra Bogovic, MD         
Sub-Investigator: Eva Ruzic-Sabljic, M.D., PhD         
Sub-Investigator: Tjasa Cerar, PhD         
Sponsors and Collaborators
University Medical Centre Ljubljana
Study Chair: Franc Strle, MD UMC Ljubljana
  More Information

Responsible Party: Franc Strle, M.D., PhD, University Medical Centre Ljubljana Identifier: NCT00910533     History of Changes
Other Study ID Numbers: LNB-0509
Study First Received: May 28, 2009
Last Updated: May 4, 2017

Keywords provided by University Medical Centre Ljubljana:
Lyme neuroborreliosis

Additional relevant MeSH terms:
Lyme Disease
Borrelia Infections
Lyme Neuroborreliosis
Central Nervous System Bacterial Infections
Bacterial Infections
Gram-Negative Bacterial Infections
Tick-Borne Diseases
Spirochaetales Infections
Central Nervous System Infections
Central Nervous System Diseases
Nervous System Diseases
Anti-Bacterial Agents
Anti-Infective Agents processed this record on May 22, 2017